Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
Recent Lassa fever outbreaks in
The National Institutes of Health (NIH) has awarded a five-year grant to
“We are extremely pleased to be part of this collaboration and to have received the NIH grant,” said
This is the second grant awarded to
Lassa fever, a serious viral disease spread by contact with infected rodents, is estimated to infect 300,000 to 500,000 people per year across
New outbreaks of the Lassa fever have been reported recently, including in
Under the NIH grant,
Dr. Garry stated that the group intends to expand this program to address other important infectious agents–such as Ebola, Marburg and other hemorrhagic fever viruses–that are of concern to the public health and bioterrorism preparedness communities.
About Corgenix Medical Corporation
About Tulane University
About Autoimmune Technologies, LLC
Autoimmune Technologies (
About Vybion, Inc.
Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.
SOURCE Corgenix Medical Corporation